Third-quarter results for Medtronic (NYSE:MDT) today included a timeline for a planned label expansion for its automated insulin delivery platform. The medtech giant posted an overall revenue miss for the three months, despite growth in the Diabetes business. (Read more about the company’s third-quarter results at sibling site MassDevice.) Speaking on the company’s earnings call […]
Medtronic
Medtronic warns on air pressure issue with certain MiniMed insulin pumps in Europe
Medtronic (NYSE:MDT) issued an urgent field safety notice in Europe related to multiple versions of its MiniMed insulin pump systems. The medtech giant’s notice includes models of the MiniMed 640G, 670G, 720G, 740G, 770G and 780G insulin pumps. During quality testing performed by Medtronic, the company said it recently found that changes in air pressure […]
Medtronic says it has next-gen insulin pumps on the way, more to come from diabetes business
The Diabetes business unit at Medtronic (NYSE:MDT) could have some exciting offering in the pipeline, company officials say. Speaking at the JP Morgan Healthcare conference this week, CEO Geoff Martha highlighted the potential opportunity in diabetes. “You’ve seen us turn around this business over the last couple of years,” Martha said. “It’s grown above our […]
The 5 most-read Drug Delivery Business News stories of 2024
There has been no shortage of news across the diabetes and drug delivery markets over the course of 2024. At Drug Delivery Business News, we’ve tried to cover it all. From product launches to major regulatory nods — with significant partnerships and integrations in between — diabetes technology particularly dominated the news over the last 12 […]
Medtronic wins FDA nod for new InPen app to support launch with Simplera CGM
Medtronic (NYSE:MDT) announced today that it received FDA clearance for its new InPen insulin delivery system application. The app features missed meal dose detection and paves the way for the launch of the company’s smart multiple daily injection (MDI) system. That system includes the recently FDA-cleared next-generation Simplera continuous glucose monitor (CGM). Medtronic’s smart MDI […]
Medtronic to submit MiniMed 780G to FDA for type 2 diabetes in 2025, updates on patch pump
Medtronic (NYSE:MDT) has plans to submit its MiniMed 780G for an expanded indication from the FDA for type 2 diabetes in the near future. On the company’s second-quarter earnings call, Que Dallara, EVP and president of Medtronic Diabetes outlined the progress on that front. “We’ve finished enrollment [in a study of MiniMed 780G for type 2 […]
The biggest diabetes tech stories of the year so far
On World Diabetes Day, it’s worth taking a look back at the last 10.5 months in the diabetes technology space. The date, which marks the birth date of the inventor of insulin, brings out all sorts of initiatives from various companies involved in innovating these technologies (read about those HERE). Those companies have contributed to […]
What diabetes tech companies are doing on World Diabetes Day 2024
World Diabetes Day — today, Nov. 14 — brings out the best in the diabetes community that continues to innovate year after year. This date serves as a time to recognize these innovations as it marks the birthday of Sir Frederick Banting. Banting discovered the insulin hormone along with Charles Herbert Best in 1922. The […]
Medtronic kicks off Blue Balloon Challenge for National Diabetes Awareness Month
Medtronic (NYSE:MDT) is kicking off another year of its Blue Balloon Challenge in recognition of National Diabetes Awareness Month. Introduced in 2021, the movement encourages people with diabetes to help drive awareness and understanding of the chronic condition. The company instructs people to take a video or photo while bouncing a blue balloon in the […]
FDA approves IDE for Medtronic Prevail drug-coated balloon
Medtronic (NYSE: MDT) announced today that it received FDA investigational device exemption (IDE) for its Prevail drug-coated balloon (DCB). The medtech giant can now begin a pivotal clinical trial for the coronary paclitaxel DCB for in-stent restenosis (ISR) and de novo small vessel disease. It plans to use data from its Prevail Global Clinical Program […]
